...
首页> 外文期刊>BMC Surgery >The ladies trial: laparoscopic peritoneal lavage or resection for purulent peritonitisA and Hartmann's procedure or resection with primary anastomosis for purulent or faecal peritonitisB in perforated diverticulitis (NTR2037)
【24h】

The ladies trial: laparoscopic peritoneal lavage or resection for purulent peritonitisA and Hartmann's procedure or resection with primary anastomosis for purulent or faecal peritonitisB in perforated diverticulitis (NTR2037)

机译:女士试验:腹腔镜腹腔灌洗或脓性腹膜炎切除术和Hartmann手术或原发性吻合术切除脓性或粪便性腹膜炎穿孔性憩室炎(NTR2037)

获取原文
           

摘要

Background Recently, excellent results are reported on laparoscopic lavage in patients with purulent perforated diverticulitis as an alternative for sigmoidectomy and ostomy. The objective of this study is to determine whether LaparOscopic LAvage and drainage is a safe and effective treatment for patients with purulent peritonitis (LOLA-arm) and to determine the optimal resectional strategy in patients with a purulent or faecal peritonitis (DIVA-arm: perforated DIVerticulitis: sigmoidresection with or without Anastomosis). Methods/Design In this multicentre randomised trial all patients with perforated diverticulitis are included. Upon laparoscopy, patients with purulent peritonitis are treated with laparoscopic lavage and drainage, Hartmann's procedure or sigmoidectomy with primary anastomosis in a ratio of 2:1:1 (LOLA-arm). Patients with faecal peritonitis will be randomised 1:1 between Hartmann's procedure and resection with primary anastomosis (DIVA-arm). The primary combined endpoint of the LOLA-arm is major morbidity and mortality. A sample size of 132:66:66 patients will be able to detect a difference in the primary endpoint from 25% in resectional groups compared to 10% in the laparoscopic lavage group (two sided alpha = 5%, power = 90%). Endpoint of the DIVA-arm is stoma free survival one year after initial surgery. In this arm 212 patients are needed to significantly demonstrate a difference of 30% (log rank test two sided alpha = 5% and power = 90%) in favour of the patients with resection with primary anastomosis. Secondary endpoints for both arms are the number of days alive and outside the hospital, health related quality of life, health care utilisation and associated costs. Discussion The Ladies trial is a nationwide multicentre randomised trial on perforated diverticulitis that will provide evidence on the merits of laparoscopic lavage and drainage for purulent generalised peritonitis and on the optimal resectional strategy for both purulent and faecal generalised peritonitis. Trial registration Nederlands Trial Register NTR2037
机译:背景技术近来,在化脓性穿孔憩室炎患者中进行腹腔镜灌洗,作为乙状结肠切除术和造口术的替代方法,报道了极好的结果。这项研究的目的是确定腹腔镜冲洗和引流对于化脓性腹膜炎(LOLA-臂)患者是否是安全有效的治疗方法,并确定化脓性或粪便性腹膜炎(DIVA-臂:穿孔型)患者的最佳切除策略DI网膜炎:乙状结肠切除术或无吻合术。方法/设计该多中心随机试验包括所有穿孔性憩室炎患者。腹腔镜检查后,化脓性腹膜炎患者接受腹腔镜灌洗和引流,Hartmann手术或乙状结肠切除术伴原发性吻合术(LOLA臂)的比例为2:1:1。粪便性腹膜炎患者将在Hartmann手术和原发性吻合术(DIVA-arm)切除术之间按1:1的比例随机分配。 LOLA组的主要综合终点是主要的发病率和死亡率。样本量为132:66:66的患者将能够检测出主要终点的差异,切除组为25%,而腹腔镜灌洗组为10%(两侧alpha = 5%,功效= 90%)。 DIVA臂的终点是初次手术后一年无气孔生存。在该组中,需要212名患者以显着证明相差30%(对数秩检验两侧alpha = 5%和功效= 90%),以支持原发性吻合术切除的患者。双臂的次要终点是存活的天数和医院外的天数,与健康相关的生活质量,卫生保健利用率和相关费用。讨论The Ladies试验是一项针对穿孔憩室炎的全国性多中心随机试验,将为腹泻型脓性全身性腹膜炎的腹腔镜灌洗和引流的优点以及化脓性和粪便性全身性腹膜炎的最佳切除策略提供证据。试用注册Nederlands试用注册NTR2037

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号